Earendil Labs secured $787 million in private financing to accelerate a broad AI‑driven biologics pipeline and expand R&D capacity across the U.S. and China. Lead investors included Dimension and Luminous Ventures, with strategic participation from Sanofi; the funding is intended to advance multiple programs toward the clinic while building an R&D organization at scale. Earendil says its platform has produced more than 40 programs, with several bispecifics, T‑cell engagers and ADCs in development and an IBD candidate ready for Phase 2. The round positions the company for larger clinical investments and a potential Hong Kong IPO while deepening partnerships with big pharma.